Glaucoma, Vision & Longevity: Supplements & Science

VisualFieldTest.com

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

  1. How Does the PreserFlo MicroShunt Stack Up Against Trabeculectomy and Other Drainage Devices?

    1d ago

    How Does the PreserFlo MicroShunt Stack Up Against Trabeculectomy and Other Drainage Devices?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/how-does-the-preserflo-microshunt-stack-up-against-trabeculectomy-and-other-drainage-devices Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction For people with open-angle glaucoma, surgical options aim to lower intraocular pressure (IOP) by creating a new drainage pathway for eye fluid (aqueous humor). The traditional gold-standard surgery is trabeculectomy, a technique that creates a small hole under a scleral flap, forming a filtering bleb under the conjunctiva. In recent years, newer implants have emerged. These include tube shunts (Ahmed, Baerveldt, Molteno implants) that channel fluid from the front of the eye to a plate under the conjunctiva, and minimally-invasive glaucoma surgeries (MIGS) such as the XEN Gel Stent and PreserFlo MicroShunt. The PreserFlo MicroShunt (formerly InnFocus MicroShunt) is a small, ab-externally implanted glaucoma device made of a soft polymer (poly(styrene-block-isobutylene-block-styrene), or SIBS). It drains fluid from the anterior chamber into a posterior subconjunctival bleb. This device is meant to be less invasive than trabeculectomy yet more effective than purely bleb-less MIGS. In this review, we compare PreserFlo to trabeculectomy and other drainage devices (Ahmed valve, Baerveldt and Molteno implants, XEN stent) in terms of how they work, clinical effectiveness, safety, practical use, and current access/cost issues. We use evidence from published trials and registries. When we report results, we note sample sizes and study years. If data are limited or mixed, we say so. Key findings are summarized in the concluding table. Background and Mechanism PreserFlo MicroShunt: The PreserFlo device is an 8.5 mm long tube with a 350 µm outer diameter and a very narrow 70 µm inner lumen (). It is made of SIBS, a biocompatible polymer that resists biodegradation (). The surgeon opens a small conjunctival/Tenon’s flap (much like for trabeculectomy) and uses mitomycin-C (an antifibrotic) under the flap. The MicroShunt is inserted ab externo: a tiny pocket is made in the sclera to accept the device fins, and a tunnel is made into the anterior chamber. The proximal tip sits inside the eye (just anterior to the iris) and the distal end drains fluid beneath the conjunctiva (see image below). Because the lumen is very small, it provides some flow resistance to help prevent severe postoperative hypotony (very low pressure). () Figure: The PreserFlo MicroShunt (red arrow) shunts aqueous humor from the anterior chamber (right) to a bleb under the conjunctiva (left) (). Trabeculectomy: In trabeculectomy, the surgeon creates a scleral flap and manually makes an opening under it (sometimes removing a small piece of iris) to connect the anterior chamber to the subconjunctival space. This creates a bleb. Mitomycin-C is often applied. Trabeculectomy is highly effective at lowering IOP, but it is invasive: it requires extensive dissection, sutures, and careful postoperative management. Tube Shunts (Ahmed, Baerveldt, Molteno): These are aqueous drainage implants. A silicone tube is inserted through the sclera into the anterior chamber. The tube drains fluid to a plate placed under the conjunctiva. The Ahmed Glaucoma Valve (AGV) includes a one-way valve designed to prevent early hypotony. The Baerveldt implant (typically 350 mm² plate) and Molteno implant (typically 275–350 mm²) are non-valved; surgeons ligate or occlude the tube temporarily to prevent immediate overdrainage. In general, valved shunts (Ahmed) cause less early hypotony but may end up at slightly higher pressures, while large non-valved shunts (Baerveldt, Molteno) can achieve lower long-term IOP but risk early overdrainage if not carefully tied off. XEN Gel Stent: The XEN 45 is a soft, gelatin-based 6 mm tube with a 45 µm lumen. It is implanted ab interno (from inside the eye) through a small corneal incision. It also drains to a subconjunctival bleb. No scleral dissection or removable flap is needed – only a gentle subconjunctival elevation of conjunctiva is done and mitomycin-C is often injected under the conjunctiva. Because the XEN lumen is slightly larger than the aqueous outflow resistance of normal trabecular pathways, it provides a controlled flow (and 45 µm lumen is internally limiting flow to avoid hypotony). However, like PreserFlo, it relies on bleb formation and often requires postoperative management (needling) of the bleb. MIGS vs Traditional Spectrum: Surgical options range from classic filtration surgery (trabeculectomy/tubes) at one end to ab interno MIGS at the other. MIGS are generally defined as procedures with an ab interno approach, minimal tissue trauma, faster recovery, and a good safety profile (). Examples of ab interno MIGS that do not form a bleb include stents in Schlemm’s canal (iStent, Hydrus) or suprachoroidal devices. PreserFlo, XEN, and older shunts are unique because they do create a bleb. These “bleb-forming MIGS” are sometimes considered intermediate: they are less invasive than trabeculectomy (especially XEN, which is minimally dissected) but not as simple as trabecular bypass stents. In practice, PreserFlo and XEN are often lumped into the MIGS group (despite ab externo steps in PreserFlo’s case) because they aim to reduce invasiveness and management burden. Efficacy Outcomes IOP Reduction and Success Rates: Clinical studies show that PreserFlo consistently reduces IOP into the mid-teens. In Baker et al. (2021), a large randomized trial of 527 eyes (395 PreserFlo, 132 trab) reported one-year IOP falls from 21.1±4.9 to 14.3±4.3 mmHg (–29% from baseline) after MicroShunt, versus 21.1±5.0 to 11.1±4.3 mmHg (–45%) after trabeculectomy (). Corresponding mean glaucoma medications dropped from 3.1 to 0.6 in the PreserFlo group and 3.0 to 0.3 in the trab group (). By Baker’s success criteria (≥20% IOP reduction without more meds), 53.9% of PreserFlo eyes and 72.7% of trabeculectomy eyes “succeeded” at 1 year (P20% IOP reduction without medications (). Mean IOP at 1 year was 12.9±3.4 mmHg (PreserFlo) and 11.4±4.5 mmHg (trab) (). Medications fell from ~2.5 to 0.4 in the PreserFlo group and to 0 in the trab group (). These results again favor trabeculectomy for lower final IOP, though both groups reached low teens pressures. Other PreserFlo series report similar IOP control. For example, Beckers et al. (2022) studied 81 eyes with PreserFlo at 2 years. Mean IOP fell from 21.7±3.4 mmHg at baseline to 14.5±4.6 mmHg at 1 year and 14.1±3.2 mmHg at 2 years (P0.0001) (). Overall success (with or without meds) was 74.1% at 1 year (). Medications dropped from 2.1 to 0.5 (mean) by 2 years, with 73.8% of patients medication-free (). In their study, higher mitomycin-C (0.4 mg/ml) trended toward better pressure and med reduction than 0.2 mg/ml (). PreserFlo vs XEN: Available data suggest similar efficacy between these two bleb-based MIGS. In a 2-year comparative series, Scheres et al. (2022) found that mean IOP dropped from 20.1 to 12.1 mmHg (PreserFlo) and from 19.2 to 13.8 mmHg (XEN) at 2 years (p=0.19) (). The probability of “qualified success” (achieving target IOP with or without meds) was 79% for PreserFlo vs 73% for XEN at 24 months (). Both groups had substantial medication reduction. Thus, in this series the two devices gave nearly equivalent pressure outcomes. PreserFlo vs Tube Shunts (Ahmed/Baerveldt): There are no head-to-head trials of PreserFlo versus tube implants. For context, device trials provide a ballpark: The Ahmed vs Baerveldt ABC Study showed at 1 year mean IOP ~15.4 mmHg with Ahmed vs 13.2 mmHg with Baerveldt when starting from 31 mmHg (). Both used adjunctive medications. These results imply that large plate tube shunts can achieve very low pressures (down to ~13 mmHg) often slightly lower than PreserFlo’s typical outcome (low teens). On the other hand, tubes carry more serious surgery for difficult cases. In practice, PreserFlo tends to be used in mild-to-moderate glaucoma; Ahmed/Baerveldt in refractory or severe cases. Longer-Term Durability: Prestigious controlled data (like Baker et al.) reported only 1-year results so far. Longer follow-up is still needed. In the Beckers 2-year series, PreserFlo pressure control was sustained at ~14 mmHg through 2 years (). Fili’s study was only 1 year. The Scheres XEN vs PreserFlo study also had 2-year data (). Notably, Baker’s trial is designed for 2 years (NCT01881425), and longer-term data should clarify durability of the MicroShunt vs trabecular outcomes. Safety and Complications Hypotony (Low IOP): Shunt surgeries often have early postoperative hypotony. In Baker et al., transient IOP ≤5 mmHg occurred in 28.9% of PreserFlo eyes versus 49.6% of trabeculectomy eyes (P0.01) (). Thus, while PreserFlo had less frequent shallow pressure than trab, more than a quarter of eyes did have an IOP hump to ≤5 mmHg after MicroShunt. Serious hypotony-related complications (maculopathy or required reformation) we Support the show

    27 min
  2. How Does the PreserFlo MicroShunt Stack Up Against Trabeculectomy and Other Drainage Devices?

    1d ago

    How Does the PreserFlo MicroShunt Stack Up Against Trabeculectomy and Other Drainage Devices?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/how-does-the-preserflo-microshunt-stack-up-against-trabeculectomy-and-other-drainage-devices Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction For people with open-angle glaucoma, surgical options aim to lower intraocular pressure (IOP) by creating a new drainage pathway for eye fluid (aqueous humor). The traditional gold-standard surgery is trabeculectomy, a technique that creates a small hole under a scleral flap, forming a filtering bleb under the conjunctiva. In recent years, newer implants have emerged. These include tube shunts (Ahmed, Baerveldt, Molteno implants) that channel fluid from the front of the eye to a plate under the conjunctiva, and minimally-invasive glaucoma surgeries (MIGS) such as the XEN Gel Stent and PreserFlo MicroShunt. ... Continue reading at https://visualfieldtest.com/en/how-does-the-preserflo-microshunt-stack-up-against-trabeculectomy-and-other-drainage-devices Support the show

    27 min
  3. Lowering Eye Pressure: The Lumigan vs Roclanda Showdown

    2d ago

    Lowering Eye Pressure: The Lumigan vs Roclanda Showdown

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/lowering-eye-pressure-the-lumigan-vs-roclanda-showdown Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Lowering Eye Pressure: The Lumigan vs Roclanda Showdown Open-angle glaucoma and ocular hypertension are conditions where intraocular pressure (IOP) is higher than normal, threatening vision. Eye drops that reduce IOP are the first-line defense. In this “showdown,” we compare Lumigan (brand of bimatoprost) and Roclanda (called Rocklatan in the US, a fixed-dose combo of latanoprost + netarsudil) – explaining how each works, how well it lowers pressure, side effects, dosing, cost, and which patients might benefit most. Mechanism of Action The two drops work differently. Lumigan (bimatoprost) is a prostaglandin analogue. Prostaglandin analogues act mainly by increasing the drainage of fluid out of the eye (especially via the uveoscleral outflow pathway). Bimatoprost is converted in the eye to a form that boosts outflow of aqueous humor, reducing pressure. For example, laboratory studies show bimatoprost lowers resistance in the trabecular meshwork by about 26% (). Clinically, bimatoprost and other prostaglandins (like latanoprost) share this main effect: more fluid drain leads to lower IOP () (). Roclanda (latanoprost + netarsudil) combines two actions. The latanoprost part is another prostaglandin, working like bimatoprost to improve outflow. On top of that, netarsudil is a Rho kinase (ROCK) inhibitor – a different class. Netarsudil’s unique action is to relax the eye’s conventional drainage meshwork (trabecular meshwork) and lower the pressure needed to push fluid out. It also has secondary effects: it can reduce pressure in the episcleral veins and even slightly reduce fluid production (). In short, while both drugs share the prostaglandin mechanism (increasing uveoscleral drainage ()), netarsudil adds a tug at the trabecular outflow route and venous side of things (). Efficacy Clinical trials show both Lumigan and the netarsudil/latanoprost combo can dramatically lower IOP, but the combo generally drops pressure further than latanoprost alone (and thus more than a single prostaglandin alone). Lumigan monotherapy typically reduces IOP by a large percentage. In trials of bimatoprost 0.03%, average drops of about 6–8 mmHg (roughly 25–35%) from baseline were seen (). For example, one analysis noted an average reduction around 7.7 mmHg. This means from a starting IOP in the mid-20s, many patients on Lumigan drop into the high teens. In fact, bimatoprost has consistently shown strong pressure-lowering: multiple studies and meta-analyses found it often lowers IOP slightly more than other prostaglandins like latanoprost (). For Roclanda/Rocklatan (netarsudil+latanoprost), phase-3 trials (the MERCURY studies) found even bigger drops compared to each drug alone. In those trials, adding netarsudil to latanoprost produced an extra 1.5–3 mmHg reduction in IOP beyond latanoprost alone (). In concrete terms, patients on the combination averaged IOPs around 15–16 mmHg at follow-up, compared to about 17–18 mmHg on latanoprost alone () (). Notably, at 3 months one study reported 42% of patients on the combo hit a mean pressure ≤15 mmHg, while only about 16–18% did so on latanoprost or netarsudil alone (). In pooled analyses, Roclanda patients had mean daytime IOP ~15–16 mmHg versus ~17–18 mmHg on latanoprost alone (). There are no direct head-to-head trials comparing Lumigan vs the netarsudil/latanoprost combo. (The recent MERCURY-3 trial compared the combo to bimatoprost/timolol rather than bimatoprost alone.) Thus we rely on separate data: prostaglandin drops like Lumigan give a strong single-agent effect, while the fixed combo can add on extra pressure reduction for those needing it. The combined drug is designed for patients not at target on a prostaglandin alone (). Side Effects and Tolerability Side effects of these drops are mostly well-known ocular reactions. Prostaglandin analogues (Lumigan’s bimatoprost and Roclanda’s latanoprost) commonly cause mild eye redness (conjunctival hyperemia), longer or thicker eyelashes, and gradual darkening of the iris color and surrounding skin () (). These changes come from the drug’s pharmacology – for example, Lumigan’s prescribing information notes pigmentation changes (iris, eyelid, lashes) and eyelash growth (). In practice, redness on Lumigan 0.01% affects about 30% of patients (); a higher 0.03% dose had more. Eyelash growth and iris darkening are not dangerous and can even be cosmetically welcome (they gave rise to Latisse eyelash formulation). However, the pigmentation changes tend to be permanent, and some patients dislike puffiness or deepening of the eye folds (“sunken eyes”) seen with prostaglandins. Overall, prostaglandin side effects are usually mild-to-moderate, but they lead many patients to notice their eyes look a bit different () (). Netarsudil, by contrast, has a distinctive side-effect profile. The most common issue is also redness – in fact, even higher than with prostaglandins. Clinical data report redness in over 50% of netarsudil-treated eyes () (). Netarsudil can also cause conjunctival hemorrhages (tiny red blood spots on the white of the eye) and corneal verticillata (whorl-like deposits on the cornea) in up to 10–20% of patients () (). For example, Rhopressa’s label notes ~53% hyperemia and about 20% cornea deposits or hemmorhages (). In Rocklatan trials, about 59% of combo patients had some hyperemia, and 11% had conjunctival bleeding and 15% had corneal deposits () (). Latanoprost’s own side effects (modest pigment/lash changes) can add to this but are relatively minor compared to the big difference in redness between netarsudil vs prostaglandin. In summary, Lumigan’s typical adverse effects: Eye redness (hyperemia) – very common (~31% on 0.01% ()). Eyelash and eyelid changes (growth, darkening) and possible eyelid fat loss () (). Iris color darkening (permanent) (). Roclanda’s common adverse effects (netarsudil + latanoprost): Hyperemia/redness – very common (~54–59% in trials) () (). Subconjunctival hemorrhage (small eye bleeds) – ~11% (). Corneal verticillata (deposits) – ~15% (). Eyelash or pigmentation changes (from the latanoprost) – generally milder than with bimatoprost. These side effects affect tolerability. In practice, up to ~40–45% of patients on a prostaglandin drop report some adverse event (), and redness is often the main complaint. The higher redness rate with netarsudil combinations can be uncomfortable – many patients describe mild stinging or a “bloodshot” eye that typically fades over time () (). Such effects do influence real-world use: patients bothered by redness or irritation may skip doses or switch drugs. (Interestingly, in the netarsudil vs latanoprost studies, some reported the red-eye of netarsudil tended to decrease after a month of nightly dosing.) Both drugs are usually given at bedtime in part to minimize noticing these effects during waking hours. Dosing and Convenience Both Lumigan and Roclanda are simple once-daily drops (usually one drop in the affected eye(s) each evening) () (). Lumigan 0.01–0.03% is instilled nightly, as is Rocklatan (netarsudil 0.02%/latanoprost 0.005%) () (). So neither requires multiple doses per day. A convenience point: Roclanda provides two active ingredients in one bottle. If a patient needs both a prostaglandin and netarsudil, using the fixed combo means only one dropper instead of two separate bottles. (For example, someone already on latanoprost who adds netarsudil could use Rocklatan and simplify their regimen.) By contrast, if a patient on Lumigan needs extra therapy, they would typically add a second bottle (another drug). The single-bottle combination can improve adherence for some patients by reducing the number of separate medications to juggle. Cost, Availability, and Approval Lumigan (bimatoprost) is a well-established medication. In the US it was originally approved in 2001 () (as 0.03%, and later 0.01%) and has parent-patent expiration spun off generics. Generic versions of bimatoprost 0.01% were approved around 2025 (). In practice, generic bimatoprost drops are now widely available, making this therapy relatively inexpensive with insurance or discount programs. (By contrast, the brand Lumigan without insurance can cost hundreds of dollars for a bottle, though coupons often reduce this.) Roclanda (latanoprost/netarsudil) is newer. The European Medicines Agency (EMA) gave approval in January 2021 (); it is marketed in the US as Rocklatan (FDA approval 2019). As a brand-name combination, it is pricier. There are currently no generic versions of the netarsudil/latanoprost combo; netarsudil itself is proprietary. Without insurance, Rocklatan’s cost is several hundred dollars for a month’s supply. Many insurance plans require patients to try simpler therapy first (for example, requiring failure of a prostaglandin drop before covering the combo). Regional differences apply: in Europe, Roclanda would be covered by national health systems similarly to other second-line glaucoma meds. Ideal Patient Profiles Lumigan (bimatoprost monotherapy) is often used as a first-choice eye drop for open-angle glaucoma or ocular hypertension () because it’s very effective and simple. It suits a patient whose target IOP is modes Support the show

    12 min
  4. Glaucoma Drainage Implants in Midlife: Decoding the Long-Term Success Rates

    3d ago

    Glaucoma Drainage Implants in Midlife: Decoding the Long-Term Success Rates

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/glaucoma-drainage-implants-in-midlife-decoding-the-long-term-success-rates Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Glaucoma Drainage Implants in Midlife: Decoding the Long-Term Success Rates Glaucoma drainage implants – also called aqueous shunts or tube shunts – are filters placed in the eye to lower pressure by draining excess fluid. They are often used when standard surgery (trabeculectomy) is unlikely to succeed or has already failed. Common devices include the Ahmed Glaucoma Valve (a valved implant), the Baerveldt Glaucoma Implant (a larger, non-valved plate), and the older Molteno implant. Newer minimally invasive options (like the XEN stent or PreserFlo micro-shunt) exist, but they are generally for milder cases and have less long-term data. Trabeculectomy is the “classic” glaucoma surgery that creates a new drain in the eye without a device. A thin flap is made and often treated with an agent (mitomycin C) to prevent scarring. By contrast, a tube implant has an artificial tube leading to a small reservoir (plate) under the eye’s surface. In effect, both aim to create a “bleb” (a drainage pocket) but trabeculectomy relies on the body’s tissues alone, whereas a tube shunt uses foreign material. Each approach has pros and cons. Tubes usually are chosen when trabeculectomy may fail (for example, if the conjunctiva is scarred or in some secondary glaucomas). Studies often compare tube shunts versus trabeculectomy head-to-head because both lower pressure but with different mechanisms and healing tendencies () (). Defining Success and Failure How do researchers judge “success” after glaucoma surgery? There is no single definition, so results can look different across studies. In general: Complete success means the eye pressure is controlled without any glaucoma medications and remains in a safe range (for example, ≤21 mmHg, often with at least a 20% drop from baseline). We measure pressure with IOP (intraocular pressure). The exact target varies (some studies use ≤18 mmHg, some ≤21 mmHg, for instance) (). Common practice is to say IOP in the mid-teens or below is a success if it’s stable. Qualified success allows glaucoma medicines. In this case the IOP is still in the target range, but the patient is using eye drops or pills in addition to the surgery. Failure is defined when the pressure is too high (above the chosen cutoff) or not lowered enough (less than the required percentage drop), or if another glaucoma procedure becomes necessary. Some definitions also count vision loss (e.g. loss of light perception) or serious complications (like uncontrollable hypotony) as failure. In short, failure generally means the surgery did not solve the problem on its own (). Because different researchers pick different pressure goals, success rates can’t be compared directly unless the definitions match (). For example, some trials counted any IOP up to 21 mmHg as success, while others needed ≤18 mmHg. It is important to note whether a reported “success rate” was complete (no meds) or qualified (with meds). Many papers report both when data is available. Long-Term Outcomes: What Do the Numbers Show? Tube Shunts vs. Trabeculectomy (TVT Study) The landmark Tube Versus Trabeculectomy (TVT) Study was a randomized trial that followed patients for 5 years () (). It compared the Baerveldt tube (350 mm² plate) to trabeculectomy with mitomycin. Key findings at 5 years (212 eyes) were: Pressure control: Both groups had similar final IOP (around mid-teens), and a similar drop in medication use (). Success (no failure) rate: 70.2% in the tube group versus 53.1% in the trabeculectomy group at 5 years (). In other words, failure (meeting failure criteria) had occurred in 29.8% of tubes and 46.9% of trab outcomes (P=0.002), showing tubes held pressure more reliably over time. Reoperation: Additional glaucoma surgery was needed much less often in the tube group (9% versus 29% in the trabeculectomy group at 5 years) (). These results suggest that after 5 years, a tube shunt was more likely to maintain target pressure than trabeculectomy in this study (for eyes that had prior cataract or trab surgery history). The IOP reduction achieved by both surgeries was similar, but trabeculectomy more often required repeat surgery. Even at 3 years of follow-up, the study showed cumulative failure rates of 15.1% for tubes versus 30.7% for trabeculectomy () (i.e., 84.9% vs 69.3% success at 3 years). In practical terms, the TVT study implies that about 30–40% of tube shunts may fail or need reoperation within 5 years, whereas trabeculectomy failure was around 47% in that timeframe () (). (Note: failure here includes not only high pressure but also tube removal, vision loss, or need for more surgery.) The pattern seen was about a 5% failure per year for tubes (), so roughly half survive at 10 years (see below). Ahmed Valve vs. Baerveldt Implant (AVB and ABC Studies) Several trials have directly compared the Ahmed valve (Ahmed-FP7) to the Baerveldt implant (BGI). Both designs are common, and understanding their long-term outcomes is important. Briefly: Ahmed FP7 has a built-in valve that resists very low pressure (so-called “flow-restricting valve”). It often lowers IOP quickly but may allow higher long-term pressures. Baerveldt (non-valved) relies on a temporary ligature (until tissue capsule forms). It can achieve lower pressures but sometimes carries a small risk of low-pressure complications (hypotony) once the ligature dissolves. Key study findings at 3 and 5 years (several hundred eyes combined): Three-year outcomes: The AVB (Ahmed vs Baerveldt) Study reported that at 3 years the cumulative failure rate was 51% with Ahmed vs 34% with Baerveldt (P=0.03) (). Mean IOP was slightly lower in Baerveldt eyes (14.4 mmHg) than Ahmed (15.7 mmHg), and Baerveldt eyes needed fewer medications (1.1 vs 1.8, P=0.002) (). Complication rates were similar, though hypotony-related issues were more common with Baerveldt. Five-year outcomes (ADB study): In a later five-year report, the AVB trial showed 5-year failure of 53% with Ahmed and 40% with Baerveldt (significantly favoring Baerveldt, P=0.04) (). The average IOP at 5 years was 16.6 mmHg (Ahmed) vs 13.6 mmHg (Baerveldt), and final medication use was 1.8 vs 1.2 drops (). Hypotony failures were 0% in Ahmed vs 4% in Baerveldt (since only the non-valved can over-drain) (). Five-year outcomes (ABC study): The ABC (Ahmed-Baerveldt Comparison) Study (a different multicenter trial) found a 5-year failure rate of 44.7% (Ahmed) vs 39.4% (Baerveldt) (not statistically different, P=0.65) (). At 5 years the IOP was 14.7 mmHg (Ahmed) vs 12.7 mmHg (Baerveldt), with about 2.2 vs 1.8 medications (). Putting it together, most trials show moderately better control with the Baerveldt implant. Roughly half of Ahmed valves and about 40% of Baerveldt implants may fail by 5 years () (), meaning about half are still successful at that point. The differences aren’t enormous, but generally Baerveldt tends to reach lower pressures and needs slightly fewer pills, at the cost of a little more risk of very low pressure. Overall success rates (complete or qualified) at 5 years are on the order of 45–60% depending on the study and definition () (). (For example, if failure is 40%, success is 60%.) Other Implants The Molteno implant is an older design (non-valved). Long-term data is sparser, but historical series suggest intermediate success rates (roughly similar ballpark as Baerveldt). Since its design is similar to Baerveldt (just smaller plate per stage), we treat it similarly but it is not commonly used today. Newer minimally invasive implants (e.g. XEN gel stent, PreserFlo MicroShunt) are smaller tubes placed via ab interno approach. These have been marketed in the last decade but have less long-term evidence. Early results indicate they can lower IOP, but often not as much as traditional tubes, and they may still fail over time. For our purposes focused on long-term outcomes, the traditional Ahmed and Baerveldt implants provide the bulk of data. Age and Device Survival (Middle-age vs Older Patients) Age can influence healing. Younger eyes tend to heal more vigorously and scar more, which can cause drainage surgery to fail sooner. Indeed, analyses from large trials confirm younger age is a risk factor for failure of tube shunts. In a pooled study of hundreds of patients from major trials (TVT, AVB, ABC), each 10-year decrease in age raised failure risk by about 19% (). In simpler terms, for example, a 50-year-old tended to have better success than a 40-year-old with the same surgery. This mirrors findings in trabeculectomy: younger patients generally scar faster, undermining the bleb. However, most published trials have mean ages in the 60s or higher. There is very little data specifically on 35–55 year olds. We extrapolate from the broader studies. Overall, middle-aged adults (e.g. 40-year-olds) may be somewhat more prone to failure than the typical study participant (who might be retired and in their 70s). But the exact drop in success isn’t sorted out in age “subgroups” in the literature. Clinically, surgeons worry that a 40-year-old’s robust healing will encapsulate the plate sooner, so we tend to expect somewhat lower long-term success in mid-life th Support the show

    23 min
  5. The Hidden Eye Risk in Athletes: Understanding Pigment Dispersion Syndrome and Pigmentary Glaucoma

    4d ago

    The Hidden Eye Risk in Athletes: Understanding Pigment Dispersion Syndrome and Pigmentary Glaucoma

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/the-hidden-eye-risk-in-athletes-understanding-pigment-dispersion-syndrome-and-pigmentary-glaucoma Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction Imagine running a race and later noticing rainbow-­like halos around lights, a brief blurring of vision, or a dull ache in your eyes. For most people this would sound alarming – yet such symptoms are often painless and temporary in a hidden condition called Pigment Dispersion Syndrome (PDS). PDS tends to strike healthy, young, myopic (nearsighted) adults, especially men in their 20s–40s. These individuals are often active and otherwise feel fine. Yet their eyes carry a concealed risk: tiny dust-like pigment granules rubbing off the back of the iris and clogging the eye’s drainage system. Over time this can raise eye pressure and lead to Pigmentary Glaucoma (PG), a form of glaucomatous nerve damage. () (). This article dives deep into what PDS is, how it can progress, and what it means for athletes and fitness enthusiasts. We’ll explain the eye’s anatomy in plain language, give clear examples from real studies, and outline the latest evidence (up to 2026) on exercise and PDS. You’ll learn why PDS often feels “silent,” how doctors spot it, and – most importantly – how people with PDS/PG can safely stay active. What is Pigment Dispersion Syndrome? The Eye’s Pigment “Dust” The iris (the colored part of the eye) has a back layer called the iris pigment epithelium, rich in dark melanin granules. In a normal eye, these pigment cells stay put. In PDS, however, the iris is slightly bowed backward and rubs repeatedly against the lens zonules (tiny fibers holding the lens). This rubbing releases pigment particles into the eye’s fluid (the aqueous humor) () (). Reverse Pupillary Block: One big factor is a “reverse pupillary block” mechanism. Normally fluid flows from behind the iris, through the pupil, to the front of the eye and drains out. In PDS eyes, however, the iris bows back like a sail (often in myopic eyes with deep anterior chambers () ()). This can create a one-way “ball-valve” effect: fluid struggles to flow forward, causing pressure behind the iris and pushing the iris even more backward. This iris concavity greatly increases rubbing between the iris pigment and the underlying structures () (). The result is repeated bouts of pigment shedding – think of it like dust collecting on a car’s windshield wipers. Where Do the Pigments Go? Once free in the eye’s aqueous fluid, the pigment granules float around and deposit on various tissues in the front of the eye (). The most important deposit is in the trabecular meshwork (TM) – the eye’s drainage grate. Pigment accumulates in the meshwork, clogging it and reducing fluid outflow () (). Over time this backs up fluid and raises intraocular pressure (IOP). Other classic signs (often seen by doctors, not by patients) include: Krukenberg Spindle: A vertical spindle-shaped band of pigment on the central corneal endothelium (the inner lining of the clear cornea) (). Convection currents in the eye cause the pigment to line up like a spindle. Iris Trans-illumination Defects: The iris develops spoke-like, radial defects that look like little gaps in a wheel when light shines through (). These are where the iris pigment cells have been stripped away. Zentmayer (Scheie) Line: A line of pigment on the back surface of the lens equator (near the top/bottom of vision). Sampaolesi Line: Pigment just in front of the Schwalbe’s line (the edge of the drainage angle). Homogeneous Angle Pigmentation: On gonioscopic exam (special mirror view of the angle), the entire trabecular meshwork is stained darkly with pigment () (). These findings – pigment showering the cornea, iris defects, and a heavily pigmented drainage angle – form the classic triad of PDS/PG () (). > Analogy: Imagine your eye’s drainage as a sponge filter. Pigment granules are like fine sand tossing into the water you pour through. Over time, the sand clogs the sponge, slowing drainage (outflow) and causing pressure to build up behind the faucet. If the outflow obstruction is significant and chronic, eye pressure rises (ocular hypertension). When this pressure damages the optic nerve (seen as thinning of nerve fibers and vision field loss), it becomes Pigmentary Glaucoma (PG) () (). In the disease spectrum, PDS is the early stage (pigment release and high pressure risk) and PG is the later stage (actual glaucoma damage) (). PDS to Pigmentary Glaucoma: Risk and Progression How Likely is PDS to Become Glaucoma? Fortunately, most people with PDS do not immediately go blind. Estimates vary, but current evidence suggests only a subset progress to true glaucoma. In clinic-based studies, about 10–50% of PDS patients eventually develop PG () (). A recent 2026 review summarized one large observation: about 10% of PDS eyes converted to PG by 5 years, and 15% by 15 years (). Earlier reviews even cited up to 50%, but those older numbers likely come from biased samples (people already in eye clinics) () (). In the general population, progression is likely at the lower end of that range, roughly 10–20% over one or two decades () (). The key risk factors for progressing from PDS to glaucoma are well documented (): High Trabecular Pigment: Eyes with a very dark, crowded trabecular meshwork (seen on exam) are at greatest risk (the “filter is nearly plugged”). Elevated Pressure from the Start: Higher baseline IOP in a PDS eye means more stress on the nerve. Younger Age: Paradoxically, younger patients may have more vigorous pigment shedding, so PDS often appears in youth and can progress more quickly. Male Sex: Men with PDS convert more often than women () (). Myopia (Nearsightedness): Moderate myopes have deeper anterior chambers and more iris-lens contact, predisposing to PDS and PG () (). Race: PG is much more common in Caucasians than in darker-pigmented eyes () (). (Many African-American or Asian patients do not show the iris transillumination defects because their eyes produce less visible pigment release, though the risk patterns are less well studied outside white populations ().) Family History: A family history suggests a genetic susceptibility. Visible Signs: Detecting a Krukenberg spindle or other pigment signs in both eyes raises the odds that glaucoma may follow (). Chronicity: A longstanding PDS (multiple years) increases odds, as pigment has more time to accumulate. The European Glaucoma Society notes that overall PDS accounts for only about 1–1.5% of all glaucoma cases, underscoring that it’s a minority form of glaucoma () (). Nonetheless, for each PDS patient, vigilance is crucial. PG tends to affect a younger population (often diagnosed in the 30–50 year range () ()) and any vision loss at that age is significant, even if total blindness is rare (). > Statistics to Note: PDS appears in about 1–2% of people (), whereas typical open-angle glaucoma is 3–4% in older adults. Of those with PDS, roughly 10–20% may develop glaucoma over time () (). There is also an age-related “burn-out” phenomenon described: as patients grow older (past 50–60), the iris often becomes less concave and sheds less pigment () (). This means PDS may slow or even abate with age. Studies have observed that older PDS patients tend to have lower IOP and slower progression (). However, any nerve damage already done is permanent, so earlier cases must be managed proactively. The Exercise Connection: What Does the Research Say? Jogging and Jumping: Triggering Pigment Release A striking theme in PDS research is the effect of physical activity. Since the 1980s, doctors have noted that jarring or high-impact exercise can provoke pigment showers and IOP spikes in PDS eyes. In a classic 1992 study, Haynes et al. had 14 PDS patients, 10 PG patients, and 10 healthy controls all do 45 minutes of jogging. They found that eyes with PDS/PG were significantly more likely to spit out pigment into the front chamber after exercise, compared to controls (). Some PDS eyes had suddenly clouded aqueous with pigment granules immediately post-run. The pressure often rose as a result, though in that small study it was modest. Interestingly, eyes on the miotic drug pilocarpine (which constricts pupils and pulls the iris taut) showed much less pigment release: in fact, pre-treatment with pilocarpine “appeared to inhibit exercise-induced pigment dispersion” (). Based on these findings, the authors concluded that not all PDS patients need to avoid exercise, but anyone who jogs or does similarly strenuous activity should get checked before and after. If heavy pigment release occurs, one strategy is starting pilocarpine drops rather than giving up the exercise (). Earlier, in 1980, Schenker et al. reported two cases of PDS patients who each had sudden painful IOP spikes after vigorous exercise (in one case, heavy lifting triggered a painful “attack” ()). These were isolated case reports, but they raised the alarm that exercise can aggravate PDS. In the late 1980s, a larger study by Smith et al. deliberately tested exercise in 10 PG patients using movements meant to jostle the lens-iris. Surprisingly, on average these glaucoma patients did not show a significant IOP rise over the two hours after exercise (). Only 2 eyes (out of 100+) had a 6–7 mmHg spike at 15 minutes, which then fell back to baseline by Support the show

    32 min
  6. Patient‑Reported Outcomes and Quality of Life After Glaucoma Procedures

    6d ago

    Patient‑Reported Outcomes and Quality of Life After Glaucoma Procedures

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/patient-reported-outcomes-and-quality-of-life-after-glaucoma-procedures Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Patient-Reported Outcome Instruments in Glaucoma Surgery Glaucoma surgery can lower eye pressure and slow vision loss, but patients care most about how their vision and daily life feel afterward. Patient-reported outcomes (PROs) capture what matters to patients – for example, how well they see, whether their eyes feel dry or irritated, and how easy it is to manage treatment. To understand these effects, researchers use questionnaires and surveys. Common vision-related questionnaires include the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) and glaucoma-specific tools like the Glaucoma Quality of Life-15 (GQL-15), which ask about difficulty with reading, driving, and performing everyday tasks (). Ocular surface symptoms (dryness, burning, grittiness) are often measured with tools such as the Ocular Surface Disease Index (OSDI) (). Treatment burden and convenience can be assessed by treatment satisfaction surveys (for example, the Treatment Satisfaction Survey for Intraocular Pressure or newer instruments like the Allergan Satisfaction with Treatment Experience Questionnaire), and some glaucoma-specific instruments now include “treatment convenience” or “ocular comfort” domains (). For instance, an adaptive GlaucomaCAT tool (GlauCAT) measures 12 domains of glaucoma quality-of-life, including visual symptoms, ocular comfort, and general convenience () (). These validated PROMs ensure we listen to patients’ perspectives after surgery. Quality of Life After Different Glaucoma Surgeries Glaucoma procedures vary widely in their effectiveness and recovery, and this shows up in patient-reported outcomes. Minimally invasive glaucoma surgeries (MIGS), often done at the same time as cataract surgery, tend to have a modest pressure-lowering effect but a gentle recovery. For example, one study of patients receiving combined cataract surgery plus a MIGS device (Hydrus or iStent) found significant improvements in patient-reported visual symptoms, ocular comfort, and general convenience (). These patients also used fewer glaucoma eye drops after surgery (an average drop count fell from about 1.8 to 1.1) and showed better tear-film tests on exam (). In other words, by relieving pressure and clearing the vision (from the cataract removal), MIGS patients reported better vision-related quality of life and fewer symptoms of dry or irritated eyes () (). In contrast, traditional filtering surgeries – trabeculectomy (making a new drainage channel) and glaucoma drainage implants (tube shunts) – usually achieve greater pressure reduction and bigger drops in medication. These bring their own trade-offs. Trabeculectomy often eliminates or greatly reduces the need for daily eye drops, but it involves a longer healing course and possible side effects (e.g. low pressure, bleb management). A large UK trial (TAGS) found that two years after surgery, patients who had trabeculectomy used about 1 drop per day on average, versus about 1.6 drops in patients managed with medications only () (). However, the same trial showed no significant difference in overall vision-specific quality of life (NEI VFQ-25 scores) between the surgical and medical groups up to 24 months (). In clinical practice and smaller studies, patients who undergo trabeculectomy often report more eye irritation (redness, foreign body sensation) and longer periods of blurred vision than those having MIGS or simpler procedures. For example, one study found that about 1–2 weeks after trabeculectomy many patients still needed patching or activity restrictions, and vision could remain blurry for up to 6 weeks () (). Comparisons among surgeries have shown meaningful differences. In one quality-of-life survey comparing trabeculectomy vs. non-penetrating canaloplasty, canaloplasty patients reported higher overall satisfaction and mood, and far fewer non-visual symptoms (like glare, burning, or stinging) than trabeculectomy patients (). Importantly, daily activities (reading, driving, socializing) were much less disrupted after canaloplasty; patients rated interference almost nonexistent, while trabeculectomy patients often needed longer recovery (). A small study of MIGS vs trabeculectomy found no significant difference in quality-of-life scores at 6 months (), but the trabeculectomy group did achieve lower pressures and larger medication drops. Glaucoma drainage implants (tubes) have a different PRO profile. Patients typically experience a slower functional recovery and more discomfort than trabeculectomy patients. One study using daily diaries reported that tube shunt implantations caused greater short-term post-op difficulty than trabeculectomy, and both glaucoma surgeries had a slower recovery of function over the following weeks compared to routine cataract surgery (). Tube patients often continue some drops afterward and may worry more about future surgeries, but objective QoL measures (NEI VFQ-25) tend to be similar between trabeculectomy and tube in cross-sectional studies (). In summary, MIGS tend to give patients a quicker, more comfortable recovery with fewer symptoms (especially when combined with cataract surgery), at the cost of somewhat less dramatic pressure lowering. Trabeculectomy and tube shunts offer powerful pressure control and often eliminate eye drops, but with longer downtime, monitoring, and more eye irritation in the short term () (). Canaloplasty provides good pressure control with a very patient-friendly profile (no bleb, minimal symptoms) (). These differences in recovery and comfort are important for patients to understand when choosing a surgery. Linking Clinical Outcomes with Patient Experience Clinical measures (eye pressure, visual acuity, visual field tests) do not tell the whole story of how patients feel. Several studies have explicitly linked patient-reported outcomes to these clinical changes. For example, after MIGS with cataract surgery, improvements in patient-reported visual symptoms and ocular comfort were driven largely by measurable gains – specifically, the better eye’s visual acuity (from the cataract removal) and lower intraocular pressure () (). In other words, when the cataract was cleared and pressure came down, patients reported less blur and dryness. Even so, recovery of daily function (answering how soon patients can read or drive) can’t be fully predicted by vision or pain alone. In a study tracking daily recovery, researchers found that after cataract, trabeculectomy, or tube surgery, early post-op vision and pain only partly explained how patients rated their functional ability (). (Patients still felt limited in activity even when acuity had returned or pain was gone.) This implies that asking patients directly about their daily activities is crucial – it uncovers issues that eye charts and pressure gauges miss. For shared decision-making, clinicians should discuss outcomes that matter most to patients. Qualitative studies consistently show patients care about practical vision goals – being able to drive, read fine print, see at night – and about treatment burden (how many drops they must use, eye discomfort from medications or surgery) () (). For instance, in interviews patients often spontaneously mentioned that continued need for eye drops was inconvenient and that they feared not being able to read or see well while driving at night. These patient-derived priorities suggest that, when choosing a surgery, doctors should explain not just the expected pressure drop but also how vision for daily tasks and comfort in the eyes are likely to improve. For example: “MIGS plus cataract surgery may not lower pressure as much as trabeculectomy, but it often clears up vision from the cataract and lets people use fewer drops () (). Trabeculectomy might mean months of careful follow-up (patches, adjustments) but can eliminate most medications () (). Together, patients and doctors can weigh these trade-offs based on what the patient values: medication freedom, clear vision, fast recovery, or maximal pressure drops.” Gaps in Long-Term PRO Data and Future Directions Despite growing interest, long-term patient-reported data on glaucoma surgeries are still limited. Many studies follow patients only a few months after surgery. For example, recent data on MIGS quality-of-life improvements typically extend only 6–12 months follow-up (). Longer-term outcomes (years after surgery) are largely unknown. It will be important to study whether early PRO gains – like improved comfort and independence – persist over time, and how they relate to maintaining vision years later. Another gap is consistency of measurement. There is no single standard PRO instrument for glaucoma surgery, and studies use a mix of general and disease-specific tools. New instruments like the GlauCAT (Computerized Adaptive Testing) show promise by covering many vision and comfort domains (), but they need more validation in diverse populations and different surgical contexts. Notably, most validated PROMs have been developed or tested in certain regions, so we need more data in underrepresented groups. Moreover, few randomized trials of glaucoma surgery include PROs as core endpoints. For example, MIGS trials focus on intraocular pressure and v Support the show

    12 min
  7. The Glaucoma Shunt Journey: What to Expect Before, During, and After Surgery

    Jun 9

    The Glaucoma Shunt Journey: What to Expect Before, During, and After Surgery

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/the-glaucoma-shunt-journey-what-to-expect-before-during-and-after-surgery Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction: The “Why” and “What” Imagine your eye as a sink that constantly produces fluid. Normally, this fluid drains out through tiny channels to keep the pressure inside your eye (intraocular pressure) in a healthy range. In glaucoma, those channels are blocked or not working well, so pressure builds up and can damage your vision. To fix this, doctors sometimes install a tiny drainpipe called a glaucoma shunt (also known as a tube shunt or aqueous shunt) in your eye. Think of it like adding a safety valve or an extra drain in the sink to let fluid out. Kaiser Permanente’s health encyclopedia describes this as placing a small plastic tube with a miniature silicone pouch in the eye to help drain fluid (). Why would a doctor suggest this? Usually, tube shunt surgery is a backup plan when more common treatments aren’t enough. If eye drops and laser surgeries can’t lower your eye pressure, or if a prior surgery has scarred over, an ophthalmologist may recommend a shunt () (). Some cases of glaucoma are extra difficult – for example, when new blood vessels grow on the iris (neovascular glaucoma) or after earlier surgeries – and a drainage implant gives another way to control the pressure () (). Remember: the goal here is not to cure glaucoma or restore lost vision, but to prevent further damage by keeping pressure low () (). In short, a glaucoma shunt is a tiny drainage device for your eye, and doctors choose it when keeping pressure low is critical and other methods aren’t doing the job () (). Preparation: Getting Ready for Surgery What should you do before the big day? First, follow your doctor’s instructions on medications. Usually, you should keep taking your glaucoma eye drops and pills exactly as prescribed until they tell you to stop. Often they even add an extra drop regimen a few weeks before surgery to get ready. For example, a UK eye hospital leaflet advises patients to continue their glaucoma medications until the time of surgery, and tells them about using a new eye drop four times a day in the lead-up () (). If you’re on blood thinners (like aspirin, warfarin, or similar), discuss this with your surgeon. Many eye teams ask patients to stop these a week before surgery to reduce bleeding risk, but only if it’s safe for your overall health (). Don’t make this decision on your own – your eye doctor will coordinate with your GP or cardiologist. Your hospital or surgical center will send you fasting instructions (for example, “no food or drink after midnight”) if you’ll be under general anesthesia (). Wear comfortable clothes and don’t bring jewelry. Importantly, arrange a ride and a helper: you will not be able to drive yourself home. You’ll likely be sedated, so plan for an adult friend or family member to escort you. As Wills Eye Hospital notes, most patients get sedation or “twilight anesthesia” during surgery and will need an adult to drive them home afterward (). Lastly, take care of yourself mentally and physically: get a good night’s sleep before, eat healthy meals up to the permitted time, and try some deep breathing or light exercise (like a short walk) the day before. Having a loved one accompany you to the hospital can ease nerves, and knowing the steps ahead can give you confidence. When you’re well prepared – both practically (meds, ride, paperwork) and mentally – you help the whole process go smoothly. The Procedure: What Actually Happens So, what happens during the surgery itself? First, you’ll go to the operating room on the scheduled day. This is usually an outpatient procedure, meaning you can go home the same day () (). You’ll lie on the surgical bed and get either local anesthesia with sedation or general anesthesia. Local anesthesia means numbing drops and injections around the eye, often combined with IV sedation (“twilight anesthesia”) so you’re relaxed and sleepy. Sometimes, especially in certain clinics, full general anesthesia (going completely to sleep) is used. The Cure Glaucoma Foundation notes that most tube-shunt surgeries use numbing injections around the eye and sedation (). In either case, you’ll feel comfortable and should not feel pain. Once you’re numb and relaxed, your eye is cleaned and covered with a sterile drape, leaving only the eye exposed. A tiny speculum (a spring-loaded clip) holds your eyelids open, so you don’t have to worry about blinking (). At this point, you may notice a bright light in your vision. Wills Eye reassures that patients often see bright lights during the operation, but because of the numbing and sedation, you should not feel any pain (). You also shouldn’t feel the surgeon’s instruments moving around. Now for the main part: the surgeon creates a small incision in the white part of your eye (the sclera). They carefully insert one end of the silicone tube into the front chamber of your eye (usually just in front of the colored iris). The other end of the tube is attached to a small plate or reservoir that sits under the conjunctiva (the thin lining over the white of the eye) under your upper eyelid () (). The device is very tiny – about 0.6 mm in diameter – and usually made of silicone or plastic (). Once in place, fluid from inside the eye can drain out through the tube to collect around the plate, then slowly seep into the body’s natural tissues. Because it sits under your eyelid, you will not see it, and you won’t feel it either () (). Often, the surgeon partially ties or fills the tube at first to prevent too much fluid from escaping too quickly. The Dudley NHS leaflet explains that a special stitch (sometimes with a material called Supramid) is used to temporarily slow flow. The stitch can later be adjusted or dissolved as needed to balance the pressure (). The surgeon then closes up the tiny incision with dissolvable stitches, and covers the part of the tube outside your eye with a patch graft (often a thin piece of donor tissue or processed tissue) so it stays covered and secure (). Finally, an eye patch and a sturdy plastic shield are taped over your eye to protect it (). In total, the surgery usually takes a couple of hours. The Cure Glaucoma Foundation notes that the surgeon’s work is about an hour, but including prep and recovery process, expect to be at the surgery center for 3–4 hours (). When it’s all done, you’ll be moved to recovery. Remember: at no point should you feel pain. If you feel discomfort or pressure, the anesthesia team can give extra numbing or sedation. Right After Surgery: The First 24–48 Hours When you wake up in the recovery room, you may feel a bit groggy (especially if you had general anesthesia) or just calm and relaxed (if you had sedation). Nursing staff will be checking your blood pressure and pulse and can give you a pain pill if needed. After surgery, your eye will still be covered by an eye pad and a hard plastic shield (). Your vision in the operated eye will be blurry at first – it’s very normal. In fact, in the first day or two, vision can be worse than before surgery (). Most people only use their unaffected eye to see clearly until the new eye heals a bit. Your other eye will still have the old vision, so rely on it for seeing while the patched eye recovers. You might feel your eye is gritty or as if something (like an eyelash) is in it () (). This scratchy/foreign-body sensation is common. The eyelid might feel heavy from the patch, and your eye will likely be red. Your doctor has given you a shield to protect that eye – you should wear it, especially if lying down or walking around at home, to avoid accidentally rubbing or bumping it. Pain is usually mild, but everyone’s tolerance differs. Your eye may ache or throb a bit as the numbing wears off. Tylenol (acetaminophen) is often recommended for discomfort (). Take any pain meds as prescribed, and don’t hesitate to call your doctor for stronger pain relief if needed. If you experience severe pain or a sudden catastrophic loss of vision, contact your doctor immediately. But mild soreness and ache are expected, and they generally improve day by day. After surgery, doctors usually restart any eye drops or medicines needed. You’ve probably been given antibiotic drops (to prevent infection) and steroid drops (to reduce inflammation). The Cure Glaucoma guide confirms you will use prescription eye drops to prevent infection and calm swelling (). Use them exactly as directed – skipping drops can increase infection risk or scarring. Rest is key. Keep your head elevated (propped up on pillows) to reduce swelling. Avoid any activity that jolts or strains the eyes. In fact, nurses might suggest taking a laxative to avoid constipation and straining (because straining at the bathroom can push pressure up in your eyes) (). Your doctor may also recommend you wear the eye shield for a few nights while sleeping to prevent you from rolling onto the eye () (). Take it easy: lie back, watch TV or listen to music, and let others help you with tasks. You did a lot – give your eye time to start healing. Short-Term Expectations: The First Few Weeks Here’s what to expect as you move into the weeks after surgery: Vision. In the days following surgery, your vision will likely remain blurry. This is totally normal. A hurried eye doctor at Wills Support the show

    20 min
  8. Targeting Very Low IOPs: Achieving Single‑Digit Pressures Safely

    Jun 7

    Targeting Very Low IOPs: Achieving Single‑Digit Pressures Safely

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/targeting-very-low-iops-achieving-single-digit-pressures-safely Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction In advanced glaucoma, doctors often set very low target pressures (often 10 mmHg or lower) to protect remaining vision () (). “Single-digit” pressures mean an eye pressure under 10 mmHg (normal pressure is 12–22 mmHg). Achieving such low pressure can slow or stop glaucoma damage, but requires strong surgery. This article explains the main surgical approaches—trabeculectomy with antimetabolites, tube shunts with flow restriction, and cyclodestruction—along with how doctors balance the benefits against risks like hypotony (too-low pressure) and vision problems. We will also cover what factors predict a surgery’s success or failure, how surgeons fine-tune eye pressure after surgery, and how to spot and treat complications early. Surgical Strategies to Achieve Low IOP Trabeculectomy with Tailored Antimetabolites Trabeculectomy (filtering surgery) creates a new drainage path for fluid (aqueous humor) to leave the eye under the eyelid. Surgeons remove a small piece of the eye’s internal drainage tissue (trabecular meshwork) and make a tiny hole into the white of the eye. A flap of tissue is sewn loosely over this opening so fluid can seep out gradually. As the fluid drains, it forms a bubble or “bleb” under the conjunctiva (the transparent tissue covering the eye). To keep this new drainage channel open long-term, surgeons often use antimetabolites (anti-scarring drugs) like mitomycin C (MMC) or 5-fluorouracil (5-FU) at the time of surgery. These drugs slow down healing so scar tissue doesn’t seal the flap shut. By carefully choosing the dose and duration of MMC, doctors can tailor how much drainage occurs. Stronger or longer MMC treatment generally increases the chance of a very low pressure, but also raises the risk of over-drainage. For example, using a high concentration of MMC (0.4 mg/ml for 4 minutes) led to hypotony (dangerously low pressure) in about 13% of cases (), whereas a lower dose (0.2 mg/ml) in a similar setting reduced that risk to 3–5% (). Modern techniques (such as injecting MMC under the conjunctiva instead of placing sponges) can achieve low pressures without excessively high hypotony rates (). Key points about trabeculectomy: It can often achieve mid-to-low single-digit pressures, especially in experienced hands () (). Surgeons use antimetabolites (usually MMC) to prevent scarring. Tuning the concentration and time of application helps find the balance between pressure lowering and safety (). The surgery can include adjustable or releasable sutures in the scleral flap. This means sutures (stitches) can be loosened or removed after surgery to increase drainage if IOP is still high, or they can be partially cut with a laser (suture lysis) if pressure is too low () (). Tube Shunts with Flow Restriction Glaucoma drainage devices (tube shunts) are small implants comprising a drainage tube and a plate. The tube is placed into the front chamber of the eye, and the plate sits under the conjunctiva on the outside. Fluid flows through the tube into a reservoir (the plate) where it is absorbed by surrounding tissues. Tube shunts are often used when previous surgeries have failed or in severe secondary glaucomas, but they can also achieve very low pressures when carefully managed. There are two main types of shunts: Valved shunts (e.g., Ahmed valve) have a built-in mechanism that partially blocks flow when pressure is low. This means they limit how low the pressure can drop automatically. Ahmed valves typically control pressure into the mid-teens. They often still require glaucoma drops after surgery. Because of the valve, deep hypotony is rare (), but extreme low targets (10 mmHg) often need additional medications or procedures. Non-valved shunts (e.g., Baerveldt, Molteno) have no built-in valve, so by default they would drain too much fluid at first. To prevent early hypotony, surgeons temporarily occlude these tubes. The standard method is to tie (ligate) the tube shut with an absorbable suture (like 6-0 or 7-0 Vicryl) around the outside of the tube. Some also place an internal stent (a thick nylon thread called Supramid®) inside the tube. As time passes (weeks to months), the ligature dissolves or the stent is removed, gradually allowing fluid out. This staged approach yields very low pressures once the eye has formed a capsule around the plate. Flow restriction techniques for tube shunts: External ligature: Tying the tube with a dissolvable suture (typically Vicryl) prevents flow for the first 4–6 weeks until the ligature softens. Some surgeons leave multiple fine sutures inside or outside that can be cut with a laser in clinic to increase flow gradually later (). Internal stent: A nylon or prolene suture (3-0 “Supramid”) is placed inside the tube lumen. This blocks most flow but can be left protruding so it can be pulled out or lasered when needed (). Fenestrations: Some surgeons create tiny slits (“Sherwood slits”) in the tube before it enters the eye. These allow a small amount of fluid to bypass the ligature early on. Because non-valved shunts ultimately allow higher flow (once fully open), they can reach lower pressures than valves, but they require careful follow-up to adjust flow. For example, one technique is to tie a Baerveldt with a loose nylon suture (10-0) that provides just ~10% occlusion on top of the main ligature. In clinic, the physician can then use a laser to cut one nylon suture at a time and “stage” the drop in pressure (). Key points about tube shunts: Valved devices (Ahmed) limit extra-low pressures but are easier to control; they often result in moderate pressure (high-teens) and usually need glaucoma drops after surgery (). Non-valved devices (Baerveldt/Molteno) can achieve very low single-digit pressures after the occluding ligature dissolves, but require temporary blocking to keep pressure safe early on () (). Post-surgical adjustments (cutting sutures, pulling stents) allow fine-tuning of IOP without major surgery. Adjunctive Cyclodestruction Cyclodestructive procedures use energy (laser or ultrasound) to partially destroy the ciliary body – the tissue that produces aqueous fluid. By reducing fluid production, these treatments help lower eye pressure. Cyclodestruction is generally used in advanced, refractory glaucoma or when other surgeries have failed or are not possible. Newer methods (like micropulse cyclophotocoagulation) aim to reduce side effects by delivering short, repeated laser pulses that heat the tissue gently (). Common cyclodestructive techniques include: Transscleral cyclodiode laser: A diode laser probe is applied on the white of the eye (sclera) over the ciliary body. It delivers burns through the sclera, shrinking fluid-producing cells (). Patients often get topical or general anesthesia for comfort. Micropulse cyclophotocoagulation: Delivers the same diode laser energy in very brief pulses, allowing the tissue to cool between bursts. This tends to cause less inflammation and pain () (). Endoscopic cyclophotocoagulation (ECP): Performed during cataract or other eye surgery, a tiny camera and laser are inserted into the eye via a small incision to directly target ciliary processes. Cyclodestruction is less predictable and generally less powerful than filtration surgery. It often lowers IOP by 20–30% on average, and is not usually enough to reach very low single digits by itself, but it can supplement other treatments. For eyes with remaining vision, doctors typically use conservative settings or micropulse to balance efficacy and safety. Key points about cyclodestruction: It is a non-incisional approach that “turns down the tap” by reducing fluid production () (). Micropulse methods cause less inflammation and usually fewer complications like pain or damage than traditional continuous-wave cyclodiode () (). Common side effects include inflammation (iritis) and potential vision loss if overtreatment occurs. Severe complications (retinal detachment, vision loss, or even phthisis) are rare with modern protocols, especially micropulse. Nonetheless, cyclodestruction is often reserved for eyes where vision is already limited or other surgeries have failed. Balancing Safety, Risks, and Follow-up Lowering eye pressure to single digits can protect vision in progressing glaucoma, but it also raises the chances of complications. Each procedure has trade-offs: Trabeculectomy: Can achieve low IOP without long-term implants, but it carries risks of overfiltration. Wounds can leak, and blebs can become too thin. Hypotony (too low pressure) after trabeculectomy can cause hypotony maculopathy – retinal folds and distorted vision (). There is also a lifelong risk of bleb-related infection (blebitis or endophthalmitis) if bacteria enter the eye through the bleb. On the plus side, trabeculectomy often achieves the lowest pressures of all procedures, especially with MMC (). Tube shunts: Generally have a safer early postoperative course regarding hypotony, especially valved implants. They also avoid an external bleb (so no bleb infection, though tubes have other risks like corneal touch or tube blockage). Non-valved shunts, once open, can still over-drain, but the staged occlusion techniques help prevent catastrophic hypotony early (). Support the show

    23 min
See All (197)

About

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

Information

You Might Also Like